March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma. The company is preparing to advance MB-105 to a Phase 2 clinical trial in early 2025, following a recently closed Series A financing round of $28.4 million. This designation acknowledges the unmet need for new treatments for this rare cancer.
This FDA decision is crucial for patients with T-cell lymphoma, who currently have limited effective treatment options and often face a poor prognosis if their cancer relapses or becomes resistant to initial therapy. The orphan drug designation validates the potential of MB-105 to address this critical gap in treatment and offers hope for improved outcomes. It also strategically positions March Bio for potential market exclusivity, a significant advantage in the competitive landscape of oncology treatments.
The orphan drug status confers substantial benefits on March Bio, including tax credits for clinical testing and exemption from prescription drug user fees. More importantly, it grants seven years of market exclusivity upon FDA approval, creating a significant commercial opportunity. This, combined with the recent Series A funding, positions the company well for the planned Phase 2 trial and future commercialization activities. The Phase 1 trial data showing a 44% overall response rate in T-cell lymphoma patients further supports the therapy’s potential.
The FDA’s recognition of MB-105 as an orphan drug reinforces the therapy’s promise and its potential to improve the lives of patients with this rare and aggressive cancer. The upcoming Phase 2 trial will be pivotal in confirming the efficacy and safety profile observed in the initial Phase 1 study. Positive results could lead to accelerated development and ultimately provide a much-needed new treatment option for patients with T-cell lymphoma.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
